3.Advancement in stimuli-sensitive drug delivery system
International Journal of Biomedical Engineering 2011;34(6):367-370
Stimuli-sensitive drug delivery system (SSDDS) is an novel drug delivery carrier.It is sensitive to either the internal physiopathologic changes (pH,temperature) of the body or external stimulus signal (ultrasound,magnetic signal) and controls the release of the drugs that it carries according to the variation of physicochemical property which stimulated by the signals.SSDDS can be prepared from hydrogels,liposomes and magnetic nanoparticles.In contrast to non-stimuli-responsive drug delivery system,SSDDS has remarkable advantages including feedback regulation,stronger controllability and targeting therapy.This paper will review the advancement in stimuli-responsive drug delivery system in recent years.
4.Correlations between the levels of glycosylated hemoglobin A1c and N-Terminal pro-Brain Natriuretic peptide in aged diabetes mellitus patients with heart failure
Chinese Journal of Primary Medicine and Pharmacy 2011;18(7):909-910
Objective To explore the correlations between the levels of glycosylated hemoglobin A1c (HbA1c)and N-Terminal pro-Brain Natriuretic peptide(NT-proBNP)in aged diabetes mellitus(DM)patients with heart failure(HF).Methods 127 patients diagnosed as DM complicated by HF and detected HbA1c and NT-proBNP when admitted into hospital,were divided into three groups according to the levels of HBA1C as follows:group A,4%≤HbA1c≤6.9%;group B,7%≤HbA1≤7.9%;group C,HbA1c≥8%.The levels of NT-proBNP were measured and compared.Results There was no statistical difference between group A and B(P>0.05),where as the levels of NT-proBNP in group C increased significantly than that in group A and B(P<0.01);In group C,HbA1c was linear positively correlated to NT-proBNP(r=0.558,P<0.01).Conclusion Aged DM patients complicated by HF,the level of HbA1c between 4%and 7.9%was acceptable.Meawhile,HhA1c should the independent risk prediction factor for aged DM patients complicated by HF,which could be used as the guide to the clinical therapy to improve the prognosis.
5.Clinical Research of Simotang Oral Liquid and Compound Glutamine Enteric Capsules for Treating Diarrhea-predominant Irritable Bowel Syndrome
Chinese Journal of Information on Traditional Chinese Medicine 2013;(8):11-14
Objective To observe the clinical efficacy of Simotang oral liquid combined with compound glutamine enteric capsules in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) belonging to liver depression and spleen deficiency pattern, and to explore its possible mechanism. Methods Sixty patients were randomly divided into two groups. The treatment goup (30 cases) took Simotang oral liquid and compound glutamine enteric capsules, the control group took Cerekinon and Medilac-S. The treatment course was 4 weeks. Clinical symptoms, 5-hydroxytryptamine (5-HT) and substance P (SP) of both groups were evaluated respectively before and after treatment. Recurrence rate and adverse reactions were recorded. Results The total effective rate after treating 1, 2, 4 weeks between the two groups had no significant difference (P>0.05). Four weeks later, in the treatment group, total score of the symptoms, abdominal distension and defecation urgency were apparently lower than that of control group (P<0.05). The levels of 5-HT and SP of the two groups significantly decreased after treatment (P<0.05). The recurrence rate at 4 weeks after drug withdrawal of treatment group and control group was 10.7%(3/28) and 32.1%(9/28) respectively. The difference between the two groups wasn’t significant (P>0.05). Obvious side effects were not found in the two groups. Conclusion Simotang oral liquid combined with compound glutamine enteric capsules has evident therapeutic effect on IBS-D of liver depression and spleen deficiency pattern, especially good at releasing abdominal distension and defecation urgency. The mechanism may be related with decreasing the levels of 5-HT and SP.
6.Clinical progress of anti-epidermal growth factor receptor antibody,cetuximab,in the treatment of colorectal cancer
Chinese Journal of Clinical Pharmacology and Therapeutics 2004;0(07):-
Recent clinical trials suggested that epidermal growth factor receptor (EGFR) targeted agents could benefit many patients with colorectal cancer. This article reviews the clinical efficacy of cetuximab, which is an antibody directed at the EGFR, in the treatment of metastatic colorectal carcinoma. Several articles about EGFR-targeted therapies in metastatic colorectal carcinoma and other solid tumors were reviewed. Cetuximab showed the increase in progression-free survival (3.98 months vs 2.56 months, P
7.The research status of preclinical animal experiments of gene therapy for Leber congenital amaurosis
Chinese Journal of Experimental Ophthalmology 2014;32(8):764-768
Leber congenital amaurosis (LCA) is extremely severe hereditary retinal dystrophy,because it leads to congenital bilateral blindness in early childhood.With the development of molecular genetics and the therapeutic gene replacement technology,gene therapy clinical trials have obtained exciting results on the basis of relatively satisfied with preliminary clinical experimental results by adeno-associated virus (AAV) vector-mediated gene therapy in the past decade.These researching methods include intravitreal injection and subretinal space injection of gene vector,and the investigating indexes include evaluations of visual function and safety,such as immune reaction of the animals,ocular histopathological change,complications and bio-distribution of gene sequence.The preliminary success of the LCAⅡ Ⅱ gene therapy will give some clues to the other inherited retinal diseases.This review focuses on the present status of pre-clinical animal experiments of its gene therapy.
9.Advance of mini-invasive treatments of hepatic portal hypertension in cirrhosis
Journal of Medical Postgraduates 2003;0(05):-
The therapeutic management of hepatic portal hypertension in patients with cirrhosis is still a challenge. At present surgical devascularization and shunting play the important roles in treatment of portal hypertension. While some cirrhotic patients can not bear the stress of operation and anesthesia because of inadequat potential hepatic function. So the mortality of operation is very high. With the development of endoscopy,radiological techniques and new materials and equipments, the mini invasive treatments become more important. This review summarizes the current advances of mini invasive treatments of portal hypertension in cirrhosis.
10.Experimental study of arsenic trioxide on rabbits with hepatic Vx-2 carcinoma by transcatheter arterial infusion
Journal of Third Military Medical University 2003;0(16):-
Objective To evaluate the anticancer effect of arsenic trioxide (As 2O 3) on rabbits with hepatic Vx 2 carcinoma by transcatheter arterial infusion (TAI). Methods Rabbits with hepatic Vx 2 carcinoma were treated with As 2O 3 by TAI for 7 d consecutively. The tumor inhibitory rate and the average tumor weight were determined. The morphological changes of the tumor were observed with a transmission electron microscope. bax/bcl 2 and VEGF expressions were examined by immunohistochemistry. Results The average weight of the tumor was 7.99, 6.50, and 4.87 g, and the tumor growth inhibitory rates in the experimental groups were 50.31%, 59 58%, and 69 71%, respectively. Tumor growth was significantly inhibited as compared with that in the NS group ( P